Description
Indication & Scope
MoMiXin® is a prescription selective phosphodiesterase 4B (PDE4B) inhibitor indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
- Mechanism: Mufemilast is a highly selective PDE4B inhibitor that increases intracellular cyclic AMP (cAMP) levels, suppresses pro-inflammatory cytokine production, and reduces chronic inflammation and keratinocyte hyperproliferation associated with plaque psoriasis.
- Drug class: Selective PDE4B inhibitor.
- Clinical use: Systemic treatment of moderate-to-severe plaque psoriasis in adults eligible for phototherapy or systemic therapy.
| Generic Name | Mufemilast Tablets |
| Brand Name | MoMiXin® |
| Ingredient | Mufemilast |
| Dosage Form | Tablet |
| Package | 15 mg per tablet |
| Conditions Treated | Moderate-to-severe plaque psoriasis |
| Taboos | Hypersensitivity to mufemilast or any component of the product |
| Place of origin | China |
| Prescription type | Prescription Drug (Rx) |
| Storage Conditions | Store in a cool, dry place and protect from moisture and direct sunlight. |
| Manufacturer | Ganzhou Hemay Pharmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20250059 |
| Date of Revision | 2025 |
| Shelf Life | Refer to the approved package labeling. |
How to use ?
Recommended Dose: The recommended dose is 60 mg orally twice daily (four 15 mg tablets per dose), approximately 12 hours apart, with or without food.
Time: Tablets should be taken twice daily at regular 12-hour intervals and swallowed whole. Do not crush, split, or chew the tablets.
Instructions for use: Mufemilast may be taken with or without food. Treatment should be continued as prescribed for long-term disease control. No routine dose adjustment is required for elderly patients or for patients with mild to moderate hepatic or renal impairment. The safety and efficacy of Mufemilast in patients under 18 years of age have not been established.
Interaction: No clinically significant drug-drug interactions have been identified to date. Mufemilast may generally be administered concomitantly with topical therapies and commonly prescribed medications, although concomitant treatment should follow the approved prescribing information.
Side effects: Common adverse reactions include mild gastrointestinal discomfort, headache, fatigue, nausea, and diarrhea. Most adverse events are mild to moderate and tend to decrease with continued treatment.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What type of drug is Mufemilast?
It is a selective phosphodiesterase 4B (PDE4B) inhibitor.
How does Mufemilast work?
It selectively inhibits PDE4B, increases intracellular cAMP levels, and suppresses inflammatory pathways involved in psoriasis.
How is MoMiXin® administered?
It is taken orally twice daily, with or without food.
What are the most common side effects?
Common adverse reactions include gastrointestinal discomfort, headache, nausea, fatigue, and diarrhea.
MoMiXin® | Mufemilast | Moderate-to-Severe Plaque Psoriasis | DengYueRX
INN: Mufemilast
Indications: Moderate-to-severe plaque psoriasis
Dosage Form: Tablets
Strength: 15 mg/Tablet
